SWX:BSLNBiotechs
Basilea Pharmaceutica (SWX:BSLN) Faces A 6% Above Fair Value View As Guidance Rises
Why Basilea Pharmaceutica stock is back in focus
Basilea Pharmaceutica (SWX:BSLN) is drawing fresh attention after reporting CHF 119 million in first half 2026 revenue and CHF 27.95 million in net income, along with higher full year guidance for both total revenue and operating profit.
See our latest analysis for Basilea Pharmaceutica.
The latest earnings and raised guidance have been met with a sharp shift in sentiment. Basilea Pharmaceutica’s share price return is 23.1% over 90 days and the...